What we lose when the most diverse populations are excluded from research.
Africa Pop.
1.4B
Global Trial Share
3%
Unique Phenotypes
100s
Knowledge Lost
Immeasurable
Key Finding
Africa contributes 18% of the world's population but only 5.9% of major-registry clinical trials, creating a 3x representation deficit.
Regional Comparison
Mental Health — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Mental Health — Computed Statistics
Africa: 174 | US: 2,996 | Europe: 1,494 | Ratio: 17.2x
Africa share: 3.7% | HHI4-region = 0.518 | Shannon H = 1.28 bits
Biomarker: AF 1,149 vs US 15,494 (13.5x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
With 18% of the world's population but only 3% of clinical trials, Africa represents the largest cognitive deficit in global medical knowledge. Hundreds of unique phenotypes — sickle cell variants, endemic cardiomyopathies, tropical infections — remain unstudied. This is not just an African problem: the entire world loses when the most genetically and phenotypically diverse population is excluded from the evidence base that drives medical practice.
The Evidence 143 words · target 156
In the epistemology of medical evidence, does the exclusion of African populations from clinical trials create a global cognitive deficit that weakens the universal validity of biomedical knowledge? This meta-epidemiological analysis compared Africa's population share (18% of 8 billion) to its trial share (5.9% of major-registry trials) using ClinicalTrials.gov data for 23,873 African trials. Investigators computed the population-to-trial ratio as the primary estimand for evidence representativeness. Africa contributes 18% of the world's population but only 5.9% of major-registry clinical trials, creating a 3x representation deficit. Unique African phenotypes including sickle cell disease (101 trials), peripartum cardiomyopathy (4 trials), and rheumatic heart disease (23 trials) remain severely understudied. The absence of Africa from the evidence base does not merely disadvantage Africans but weakens the scientific validity of findings presumed to be universal. Interpretation is limited by the exclusion of non-ClinicalTrials.gov registries and observational studies.
Sentence Structure
Question
In the epistemology of medical evidence, does the exclusion of African populations from clinical trials create a global cognitive deficit that weakens the universal validity of biomedical knowledge?
Dataset
This meta-epidemiological analysis compared Africa's population share (18% of 8 billion) to its trial share (5.9% of major-registry trials) using ClinicalTrials.gov data for 23,873 African trials.
Method
Investigators computed the population-to-trial ratio as the primary estimand for evidence representativeness.
Primary Result
Africa contributes 18% of the world's population but only 5.9% of major-registry clinical trials, creating a 3x representation deficit.
The absence of Africa from the evidence base does not merely disadvantage Africans but weakens the scientific validity of findings presumed to be universal.
Boundary
Interpretation is limited by the exclusion of non-ClinicalTrials.gov registries and observational studies.